Efficiency of treatment of chemoresistant tuberculosis from patients suffering from HIV in Zaporizhzhia region within 2013–2017
Purpose of the study. Is to study the efficiency of treatment of tuberculosis from patients suffering from chemoresistant tuberculosis associated with HIV under the conditions of Zaporizhzhia region during 2013–2017.
Materials and methods. 379 cases of chemoresistant tuberculosis associated with HIV infection were registered in Zaporizhzhia region within 2013–2017. The efficient of treatment of tuberculosis from patients suffering from tuberculosis/HIV co-infection was estimated according to the data of cohort analysis.
Results and discussion. The results of treatment of tuberculosis from HIV positive patients suffering also from the resistant tuberculosis were very low in 2015; the efficient treatment and the lethality were on the same level – 31,9%. The lethality increased by 1,3 times as compared to 2014. The efficient treatment was only in 41,8% in 2016. There was a high percent of discontinued treatment from patients with resistant forms due to long period of treatment: 25,2% in 2015 and 23% in 2016.
The improvement of provision of psychological aid to the patients suffering from tuberculosis/HIV co-infection during treatment is a promising trend. Treatment of patients suffering from chemoresistant tuberculosis associated with HIV was estimated as an efficient after additional counseling for 20 patients (57,1%); 5 patients (11,4%) discontinued antitubercular chemotherapy; 6 patients (17,1%) had a treatment failure; there were 5 fatal cases (14,4%).
Conclusions. The efficiency of treatment of chemoresistant tuberculosis from HIV positive patients in Zaporizhzhia region during 2013–2017 was equal to 41, 45, 31,9, 41,8 and 34,5 percents, respectively, according to the data of cohort analysis. It is necessary to implement the new tests for diagnosis and new treatment regimens for the purpose of the improvement of the efficiency of treatment of chemoresistant tuberculosis from HIV positive patients. However, this will be insufficient without improvement of individual psychological work with patients.
Melnik VM, Novozhilova IO, Matusevich VG. Psychological assistance to patients with tuberculosis. Ukrayinskyy pulmonolohichnyy zhurnal. 2019; 2: 63–71.
Pyatnochka IT, Kornaha SI, Tkhorik NV. The shortcomings and their elimination analysis is the key to reducing the spread ofchemoresistant tuberculosis. Visnyk sotsialnoyi hihiyeny ta orhanizatsiyi okhorony zdorovya Ukrayiny. 2016; 1: 41–44.
Andrushchak MO. Characteristics of opportunistic infections arising from stage III–IV in HIV-infected people. Zaporizkyy medychnyy zhurnal. 2017; tom19, 2 (101): 217–220.
Pokrovsky VV, Ladnaya NN, Sokolova EV. HIV infection and tuberculosis in Russia: «Both are worse». Tuberkuloz i bolezni logkikh. 2014; 6: 3–8.
Esmail H, Riou C, Bruyn ED et al. The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons. Annu Rev Immunol. 2018; 36: 603–638. DOI: 10.1146/ annurev-immunol-042617-053420.
Eshetie S, Gizachew M, Alebel A, van Soolingen D. Tuberculosis treatment outcomes in Ethiopiafrom 2003 to 2016, and impact of HIV coinfectionand prior drug exposure: Asystematic review and meta-analysis. PLOS ONE. 2018; 13 (3): e0194675. DOI: 10.1371/journal.pone.0194675.
Wejse C, Patsche CB, Kuhle A et al. Impactof HIV-1, HIV-2, and HIV-1+2 dual infectionon the outcome of tuberculosis. International Journal of Infectious Diseases. 2015; 32: 128–143. DOI: 10.1016/j.ijid.2014.12.015.
Тciko OV. HIV/TB co-infection in the structure of the incidence of pulmonary pathology in HIV-positive persons (according to the materials of the medical archive of the Regional Clinical Infectious Hospital, Kharkiv for the period 2013–2017). Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2019; 2: 78–84.
Mendez-Samperio P. Diagnosis of Tuberculosis in HIV Co-infectedIndividuals: Current Status, Challenges and Opportunities for the Future. Scand J Immunol. 2017; 86 (2): 76–82. DOI: 10.1111/sji.12567.
Prado TN, Rajan, JV, Miranda AE et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment out comes in TB-HIV co-infected patients in Brazil: a hier archical polytomous analysis. Braz J Infect Dis. 2017; 21 (2): 162–170. DOI: 10.1016/j.bjid.2016.11.006.
Liskin IV, Zagaba LN, Nikolaevа OD. Pulmonary pathology and causes of death among hospitalized adult patients with HIV infection: pathological analysis. Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2019; 2 (37): 24–34.
Marchenko NA. Efficacy and tolerability of antimycobacterial chemotherapy against antiretroviral therapy in patients with new cases of tuberculosis / HIV co-infection. PhD. 2015. Kyiv. Ukraine.
Dobkina MN, Solovyova SA, Chernov AS et al. Organization of treatment of patients with combined pathology of HIV / tuberculosis in the Tomsk region. Tuberkuloz i bolezni logkikh. 2014; 1: 91–94.
Feshchenko YI, O. Cherenko SB, Matveyeva OJ et al. Adverse reactions of antituberculosis drugs in the process of evaluating the effects of treatment of patients with tuberculosis. Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2014; 4: 13–20.
Protsyuk RH. Тopical issues of tuberculosis/ HIV/AIDS co-infection in Ukraine. Tuberkul'oz, lehenevi khvoroby, VIL-infektsiya. 2016; 1: 21–26.
Okromeshko SS, Hamazina KO, Leontieva SL, Vaytek E. Socio-economic support for patients with multidrug-resistant tuberculosis as an effective way of reducing treatment discontinuities. Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2017; 1: 12–15.
Streltsov VV, Zolotova NV. Psychological rehabilitation of tuberculosis patients in the phase of intensive treatment. Кonsultativnaya psikhologiya i psikhoterapiya. 2013; 1: 10–19.
Petrenko VI, Panasyuk VO, Radish GV et al. Comparative results of treatment of patients with tuberculosis (unspecified localization, rifampicin resistant lung, multiresistant lung, miliary and multiresistant nervous system) in combination with HIV. Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2017; 1: 84–92.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.